

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

RESIGNATION OF CHIEF FINANCIAL OFFICER

The board of directors (the “**Board**”) of Ascentage Pharma Group International (the “**Company**”) hereby announces Mr. Su Zhang (“**Mr. Zhang**”), has decided to resign from the office of the Chief Financial Officer of the Company due to his other business commitments which require more of his time and dedication, with effect from November 1, 2021.

The Company wishes to express its appreciation for Mr. Zhang’s invaluable contributions during his tenure of office. Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter which needs to be brought to the attention of the shareholders of the Company in respect of his resignation.

The Company will look for a candidate to fill the above vacancy as soon as possible and further announcement will be made in compliance with the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited as and when appropriate.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, November 1, 2021

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.